The Perspective of Healthy Individuals on Breast Cancer Risk Prediction Report In The Indonesian Population

Summary

In 2016, a meta-analysis showed that DNA-based risk reporting alone does not facilitate behavior change. However, there have been several studies showing that tailoring care plans related to diet may help with adherence to a tailored diet plan.

Risk prediction report displays both Polygenic Risk Score (PRS) and modifiable (non-genetic) risk factors. Overtime, the investigators aim to combine both PRS and modifiable risk factors to have a localized and stronger prediction model for the local population. The risk prediction report is designed to tailor care plans for patients by their physicians or care planner.

Focus groups allow deeper discussions in themes important to guide design of the report. This method has been used in previous similar studies, such as one by Cutting et al to understand physicians' preference in integrating genetic reports into daily practice. Studies also have shown that local adoption of personalized medicine and care is hindered by limited infrastructure of information management and awareness, despite personalized medicine being widely adopted in healthcare systems in developing countries.

Conditions

• Breast Cancer

Interventions

OTHER

Focus Group Discussion

Each focus group will consist up to five participants in every session, two sessions each for both low and high risk group. Every FGD sessions will last for 1 to 2 hours and be conducted in Indonesian, and will be recorded. Both groups will be asked the following questions: 1) What is your opinion regarding the clarity of information in the dummy breast cancer risk prediction report?; 2) What is your opinion regarding the completeness of information in the dummy breast cancer risk prediction report?; and 3) What is your impression regarding the results presented in the dummy breast cancer risk prediction report?.

Sponsors & Collaborators

• SJH Initiatives

  collaborator UNKNOWN

• MRCCC Siloam Hospitals Semanggi

  collaborator UNKNOWN

• Nalagenetics Pte Ltd

  lead INDUSTRY

Principal Investigators

• Samuel J Haryono, Ph.D., MD · SJH Initiatives

• Faustina A Agatha, S. Biotek · SJH Initiatives

• Fatma Aldila, MPH · Nalagenetics Pte Ltd

• Eric A Fernandez, Ph.D. · Nalagenetics Pte Ltd

• Sabrina G Tanu, B. Sci · Nalagenetics Pte Ltd

Study Design

Allocation

NA

Purpose

OTHER

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

25 Years

Max Age

75 Years

Sex

FEMALE

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2022-11-08

Primary Completion

2023-02-12

Completion

2023-02-12

Countries

• Indonesia

Study Locations